Physician profile
Anna Harris
NPI 1780879551
$1,110.25
in general payments reported to CMS, 2019-2025
26 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2022: $231 · 2023: $132 · 2024: $380 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $107.34 | 2022-2025 | |
| Angiodynamics, INC. | $106.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $81.69 | 2022-2025 | Enhertu, Lynparza, Imfinzi |
| Progenics Pharmaceuticals, INC. | $77.92 | 2022-2024 | Pylarify |
| Abbvie INC. | $76.86 | 2024-2025 | |
| Novocure INC. | $74.85 | 2019-2023 | Optune |
| Octapharma USA, INC. | $67.37 | 2022-2025 | Octagam Immune Globulin (Human) |
| Sobi, INC | $61.45 | 2022-2024 | |
| Tersera Therapeutics LLC | $58.39 | 2024-2025 | Xermelo, Zoladex |
| Pharmaessentia USA Corporation | $39.25 | 2024 | Besremi |
| Janssen Biotech, INC. | $37.14 | 2024-2025 | Balversa, Erleada, Rybrevant |
| Merck Sharp & Dohme LLC | $33.74 | 2024 | Keytruda, Welireg |
| Eisai INC. | $32.87 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.78 | 2025 | Ninlaro |
| Genzyme Corporation | $28.81 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $23.82 | 2024 | Jakafi |
| Coherus Oncology, INC. | $20.91 | 2023 | |
| Genentech USA, INC. | $20.15 | 2024 | Tecentriq |
| Emd Serono, INC. | $18.47 | 2024 | |
| Morphosys, US INC. | $17.99 | 2022 | |
| Stemline Therapeutics INC. | $17.81 | 2023 | Orserdu |
| Alexion Pharmaceuticals, INC. | $17.35 | 2023 | Ultomiris |
| Genmab U.S., INC. | $16.82 | 2024 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $15.36 | 2022 | |
| Pfizer INC. | $15.05 | 2024 | |
| Fortovia Therapeutics, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.